# A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

> **NCT06007690** · PHASE3 · RECRUITING · sponsor: **Aura Biosciences** · enrollment: 100 (estimated)

## Conditions studied

- Choroidal Melanoma
- Indeterminate Lesions
- Uveal Melanoma
- Ocular Melanoma

## Interventions

- **DRUG:** Bel-sar
- **DEVICE:** Suprachoroidal Microinjector
- **DEVICE:** Infrared Laser
- **DEVICE:** Sham Infrared Laser
- **DEVICE:** Sham Microinjector

## Key facts

- **NCT ID:** NCT06007690
- **Lead sponsor:** Aura Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-06
- **Primary completion:** 2027-11-15
- **Final completion:** 2028-08-15
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06007690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06007690, "A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06007690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*